Effectiveness of Mitomycin C Combined with Amniotic Membrane Transplantation to Treat Recurrent Pterygia. |
Young Hoon Jung, Byung Yi Ko |
Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Korea. kopupil@hanmail.net |
양막을 이용한 재발 군날개수술에서 마이토마이신 C의 효과 |
정영훈⋅고병이 |
건양대학교 의과대학 안과학교실 |
Correspondence:
Byung Yi Ko, Email: kopupil@hanmail.net |
Received: 14 December 2017 • Revised: 9 January 2018 • Accepted: 19 February 2018 |
Abstract |
PURPOSE We evaluated a combination of intraoperative mitomycin C (MMC) and amniotic membrane transplantation (AMT) for treating recurrent pterygia. METHODS: We retrospectively analyzed 40 eyes of 39 patients with recurrent pterygia who underwent AMT from December 2007 to July 2015 and who were followed-up for a minimum of 12 months. In all, 22 eyes received intraoperative MMC (group A) and 18 did not (group B). Recurrence rates and complications were compared between the two groups. RESULTS: Conjunctival recurrence was noted in two and corneal recurrence was noted in four eyes of group A (27.3%); the figures for group B were four and three (38.9%). These recurrence rates were not significantly different (p = 0.545). In five cases with preoperative symblepharon, this condition recurred when MMC was not used (two eyes) but not when MMC was used (three eyes). No major complications such as necrotizing scleritis, scleromalacia, or corneal ulcer were observed in either group after surgery. CONCLUSIONS: Intraoperative adjunct MMC therapy did not significantly inhibit recurrence after AMT for treating recurrent pterygia but may reduce the recurrence rate of symblepharon. |
Key Words:
Amniotic membrane transplantation;Mitomycin C;Recurrent pterygium;Symblepharon |